Ptc Therapeutics (PTCT) | Stock Overview & Key Data
Ptc Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $78.72 on April 6, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ptc Therapeutics
PTCT
|
5.69B Mid-cap | 5.88% | 0.16% | 18.59% | -0.66% | -2.08% | 46.59% | 74.62% | 68.32% | 1,001.76% | 329.37% | 329.37% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Arrowhead
ARWR
|
10.42B Large-cap | 4.45% | 0.63% | 34.48% | 12.71% | 13.81% | 373.44% | 110.51% | -12.98% | 1,198.26% | 1,520.00% | 55.90% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | 7.77% | 11.28% | 60.15% | 73.28% | 41.81% | 145.12% | 200.20% | 278.87% | 3,924.76% | 2,713.34% | 2,713.34% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 6.69% | 29.72% | 15.08% | -4.29% | -5.83% | 6.89% | -31.20% | -49.99% | 96.15% | 179.21% | 318.28% |
Ownership & Short Interest
Calculate Your Ptc Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Ptc Therapeutics stock price in Jul 2016 was $7.18, A $1,000.00 lump sum investment in Ptc Therapeutics made 8 years ago would be worth approximately $7,077.99 today, representing a exceptional return of 607.80%. This translates to an annualized return (CAGR) of 24.52%.
8 Years 11 Months Investment Scenario (Jul 2016 - Jun 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is PTCT's 52-week high and low?
- In the last 52 weeks, Ptc Therapeutics reached a high of $58.38 (on March 17, 2025) and a low of $28.72 (on June 28, 2024).
- What is the market cap and P/E ratio for PTCT?
- Curious about Ptc Therapeutics's size and valuation? Its market capitalization stands at 5.69B. When it comes to valuation, the P/E ratio (trailing twelve months) is 8.01, and the forward P/E (looking ahead) is 28.27.
- Does PTCT pay dividends? If so, what's the yield?
- As for dividends, Ptc Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ptc Therapeutics's main competitors or similar companies to consider before investing?
When looking at Ptc Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Arrowhead
ARWR10.42B Healthcare Biotechnology 373.44% 110.51% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 145.12% 200.20% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.89% -31.20% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ptc Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Ptc Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -332.49%, the Debt to Equity ratio from the most recent quarter is -13.19, and its Gross Profit Margin stands at 95.78%.
- What is the recent revenue and earnings growth for PTCT?
- Looking at Ptc Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -22.70%, and quarterly earnings saw a YoY growth of -22.75%.
- How much of PTCT stock is held by insiders and institutions?
- Wondering who owns Ptc Therapeutics stock? Company insiders (like executives and directors) hold about 7.43% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 113.38%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.